Plain-English translation of NCT07791199 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a continuation study for people who have already completed an earlier research trial testing for lupus, Sjögren's disease, psoriasis, or psoriatic arthritis. If you finished one of the original studies and benefited from the medication, this trial lets you keep taking it rather than stopping. The medication works by helping calm down an overactive immune system that causes these conditions.
Once early studies show a treatment is working and safe, researchers want to make sure people can continue access to the medication while they work toward getting it approved by the FDA. This trial ensures that people who are doing well don't have to stop their treatment during the wait for final approval.
You will continue taking the same medication you were taking in your earlier study. You'll likely have regular check-in visits with your doctor to make sure the treatment is still working well and isn't causing problems. The exact schedule and length of the trial will depend on your individual situation and what your doctor recommends.
AI-generated summary from trial data · Aug 31, 2026 · Not medical advice
Phase
Large-scale testing
Sponsor
Bristol-Myers Squibb
Enrollment target
~2,300 participants
Started
December 2026
Primary completion
October 2030
Age range
4 Years – 75 Years
Last updated on clinicaltrials.gov in September 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Bristol-Myers Squibb
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.